SCHEDULE: Lilly Endowment Reports 9.6% Stake in Eli Lilly

Lilly Endowment, Inc. has disclosed a beneficial ownership of 90,376,978 shares of Eli Lilly and Company common stock, representing 9.6% of the outstanding shares as of June 30, 2026.

Summary

• Lilly Endowment, Inc. has filed a Schedule 13G, indicating its beneficial ownership of Eli Lilly and Company common stock.
• As of June 30, 2026, Lilly Endowment, Inc. holds 90,376,978 shares of Eli Lilly common stock.
• This holding represents 9.6% of the total outstanding common stock.
• The percentage is based on 941,741,406 shares outstanding as of April 27, 2026, as reported in Eli Lilly's Form 10-Q.
• Lilly Endowment, Inc. has sole voting power and sole dispositive power over these shares.
• The filing is an amendment (Amendment No. 46) to a previous Schedule 13G filing.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral; it's a routine disclosure of a significant, long-standing ownership stake rather than an indicator of new developments or strategic shifts.

Positives

• Lilly Endowment, Inc. maintains a significant, stable ownership stake in Eli Lilly and Company.
• The Endowment has full control over voting and disposition of its shares.

Risks

• Concentration of ownership by a single entity (Lilly Endowment, Inc.) could potentially influence corporate decisions in ways that may not align with other shareholders.
• Changes in the Endowment's investment strategy or philanthropic needs could lead to significant sales of Eli Lilly stock, impacting market price.

Future Outlook

No specific forward-looking statements or guidance are provided in this Schedule 13G filing, as it pertains to reporting existing beneficial ownership.

Industry Context

StockSavvy.ai notes that large, long-term holdings by endowed institutions like Lilly Endowment are common in the pharmaceutical sector, often reflecting historical ties and a belief in the company's long-term prospects. This filing confirms the continued significant influence of the Endowment.

Stakeholder Impact

• Shareholders: The continued significant holding by Lilly Endowment, Inc. suggests stability in a major shareholder, but also highlights potential for large block trades if the Endowment's strategy changes.
• Eli Lilly and Company: The Endowment's substantial stake implies a vested interest in the company's performance and governance.

Next Steps

• Lilly Endowment, Inc. will continue to report any material changes in its beneficial ownership of Eli Lilly and Company stock as required by SEC regulations.

Key Dates

Keywords

Eli Lilly and Company, Lilly Endowment, Schedule 13G, Beneficial Ownership, Common Stock, Shareholder